Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 85

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 85
---
, the foregoing discussion and table do not take into account further dilution to investors in this offering that could occur upon the exercise of outstanding options and warrants, including the Pre-Funded Warrants and Series Warrants offered in this offering, having a per share exercise price less than the public offering price per share in this offering. The foregoing discussion and table also does not take into account any “alternative cashless exercises” of the Series B Warrants, pursuant to which a holder of a Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Series B Preferred Stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0 The discussion and table above are based on 10,014,872 shares of our common stock outstanding as of September 30, 2024, and excludes the following:

| ● | 8,188,742 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $14.49 per share; |

| ● | 509,133 shares of common stock underlying outstanding options of the Company, with a weighted average exercise price of $4.75 per share; |

| ● | 560,171 shares of common stock issuable upon conversion of the 1,039 shares of the Company’s Series A Preferred Stock outstanding, at a conversion price equal to $2.25 per share; and |

| ● | 2,158,658 shares of common stock reserved for issuance under the Plan. |

The discussion and table above assume no sale of Pre-Funded Warrants or Series Warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one -for-one basis. To the extent that our outstanding options or warrants are exercised, new options or RSUs are issued under our equity incentive plan, or additional shares of our common stock are issued in the future, there may be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

47

### UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATE